Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Patent
1996-05-24
1999-11-16
Campell, Bruce R.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
800 9, A61K 4900, C12N 500
Patent
active
059852437
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to a murine model for human infection by Helicobacter pylori (H.pylori). The model is especially useful for the development of vaccines against H. pylori.
BACKGROUND OF THE INVENTION
Helicobacter pylori was isolated in 1982 by B. Marshall and J. Warren using microareophilic conditions that had been developed to grow Campylobacter jejuni. H. pylori bacteria are S-shaped, gram negative bacilli 2-3.5 .mu.m in length and 0.5-1 .mu.m in width. The cell wall is smooth and adheres closely to the cytoplasmic membrane. H. pylori is responsible for the most common infection in the world. In developing countries 80% of the population is infected by the bacterium at the age of 20, while in developed countries H. pylori infection increases with age from <20% in 30-year old people to >50% in 60-year olds (Megraud, Gastroentrol. Clin. North Am., 1993, 22, 73-88; Taylor and Blaser, Epidemiol. REv., 1991, 13, Graham, J. Gastroenterol. Hepatol., 1991, 6, 105-113). The bacterium is probably transmitted by the oral-fecal route. Presently, there are two theories to explain the acquisition of H. pylori. One states that infection occurs during the first years of life and persists forever (cohort effect). The other purports that the acquisition of infectious bacteria occurs continuously, at a rate of 0.5-2% per year and, once established, the infection is chronic, possibly permanent. Risk factors for infection are crowding, poor hygiene and host-specific genetic factors.
Colonization of the mucosa of the stomach and the duodenum by Helicobacter pylori is today recognized as the major cause of acute and chronic gastroduodenal pathologies in humans (Blaser, Gastroenterology, 1987, 93, 371-383). The recognition of the infectious nature of the illness is having a major impact in the treatment of the disease that is shifting from the treatment of symptoms by anti-H2 blockers to the eradication of the bacterial infection by antibiotic regimen.
In spite of the unquestionable successes that will be achieved with antibiotic treatment, it should be remembered that this inevitably leads to the occurrence of resistant strains that in the long term will make antibiotics ineffective. This suggests that vaccination, which classically is the most effective way to prevent and control infectious diseases in a large population, could be used to prevent infection and possibly also to treat the disease (Rappuoli et al., J. Gastroenterol. Hepatol., 1993, 5 (Suppl. 2), 76-78).
Vaccine development requires understanding of a number of critical steps that are not yet fully studied. These are: immunogenicity of the molecules identified, immunity that is necessary to confer protection against infection and disease.
One of the most pressing needs is the development of an animal model in which to study H. pylori infection. Gnotobiotic piglets and beagle dogs can be artificially infected by H. pylori. In adult humans chronic H. pylori infection is associated with infiltration with neutrophils and mononuclear cells, whereas in infected children the lamina propria is infiltrated mainly by lymphocytes. Gnotobiotic piglets and dogs infected with H.pylori have a gastritis that is much more similar to the response seen in children with the inflammatory infiltration consisting mainly of lymphoplasmacytic cells with very few neutrophils. Thus these two infection models can only reproduce a pathological picture observed in a limited percentage of human patients. Non human primates have been reported to be naturally infected by H.pylori; the gastritis observed is more similar to that observed in the infected adult humans. Nonetheless, no evidence of H.pylori-dependent peptic ulceration has been reported in this animal model. A major problem with H.pylori infection of gnotobiotic pigs, dogs and monkeys is also the fact that these models are very expensive and have special housing requirements.
An animal model has been established by infecting germ-free mice with Helicobacter felis. The infection is characterized by an inflammatory
REFERENCES:
patent: 5625124 (1997-04-01), Falk et al.
M Karita et al (1994) American J Gastroenterology 89: 208-213.
L Marzio et al (1994) Gastroenterology 106: A129.
M Karita (1991) American J Gastroenterelogy 86: 1596-1603.
P Ghiara et al. (1994) American Journal of Gastroenterology 89: 1319, abstracts 136 and 137.
K Saukkonen (1988) Microbial Pathogenesis 4: 203-211.
L-T Hu et al. (1992) Infection and Immunity 60: 2657-2666.
Webster's Ninth New Collegiate Dictionary (1990) p. 877.
G Audesirk et al (1986) Biology Life on Earth pp. 355-357, 367.
Blaser, "Gastric Campylobacter-like Organisms, Gastritis, and Peptic Ulcer Disease", Gastroenterology, 1987, 93, 371-383.
Ghiara et al., "Infection by Helicobacter pylori in a mouse model that mimics human disease: protection by oral vaccination", GUT, 1995, Abstract No. 204.
Ghiara et al., "Colonization of Murine Stomach by Fresh Isolates of Helicobacter Pylori", Am. J. Gastroenterol., 1994, 89(8), 1319, Abstract No. 137.
Hu et al., "Purification of Recombinant Helicobacter pylori Urease Apoenzyme Encoded by ureA and ureB", Infect. Immunity, 1992, 60(7), 2657-2666.
Karita et al., "New Small Animal Model for Human Gastric Helicobacter pylori Infection: Success in Both Nude and Euthymic Mice", Am. J. Gastroenterology, 1991, 86(11), 1596-1603.
Karita et al, "Establishment of a Small Animal Model for Human Helicobacter pylori Infection Using Germ-Free Mouse", Am. J. Gastroenterology, 1994, 89(2), 208-213.
Marchetti et al., "Development of a mouse model of Helicobacter pylori infection that mimics human disease", Science, 1995, 267(5207), 1655-1658.
Marzio et al., "Gastric Ulcer and Antral Gastritis Experimentally Induced by Human Helicobacter Pylori in Bacillary and Coccoid Form in Balb/C Euthymic Mice", Gastroenterology, 1994, 106(4), A129.
Matsumoto et al., "Metronidazole resistant mutant isolated from H. pylori infected euthymic mice model", GUT, 1995, 37, A49.
Megraud, "Epidemiology of Helicobacter Pylori Infection", Gastroenterol. Clin. North Am., 1993, 22, 73-88.
Rappuoli et al., "Pathogenesis of Helicobacter pyroli and perspectives of vaccine development against an emerging pathogen", Behring Institute Mitteilungen, 1994, 95, 42-48.
Rappuoli et al., "Development of a vaccine against Helicobacter pylori: a short overview", Eur. J. Gastroenterol. Hepatol., 1993, 5(Supp. 2), S76-S77.
Saukkonen, "Experimental meningococcal meningitis in the infant rat", Microb. Pathogenesis, 1988, 4, 203-211.
Taylor et al., "The Epidemiology of Helicobacter pylori Infection", Epidemiol. Rev., 1991, 13, 42-59.
Blackburn Robert P.
Campell Bruce R.
Chiron S.p.A.
Harbin Alisa A.
LandOfFree
Mouse model for Helicobacter pylori infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mouse model for Helicobacter pylori infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mouse model for Helicobacter pylori infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1320501